TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03626246

Intervention type: OTHER
Intervention: Kidney disease
Description: Being part of this study you agree to participate in all these interventions:~Genetic:~• Blood sample~Procedure/Surgery:~• Bone and muscle biopsies.~Radiation:~* Bone density (DXA)~* Thoracic and lumbar spine plain films.~* HRpQCT: high-resolution peripheral quantitative computed tomography~Other:~* Completing medical history, physical activity level, and dietary questionnaires for calcium and vitamin D.~* Measure levels of Advanced Glycation End products (AGEs) in the skin.
Study: NCT04507646

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: True auricular acupuncture
Description: The participant in experimental group will receive acupuncture on ear Shenmen point, ear zero point, and Salivary glands.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham auricular acupuncture
Description: The participant in control group will receive acupuncture on ineffective point at ear.
Study: NCT00782210

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
Study: NCT04400097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: suture
Description: suture methods of autograft conjunctival transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Description: suture methods of autograft conjunctival transplantation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suture
Description: suture methods of autograft conjunctival transplantation
Study: NCT03701516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with novel molding process
Description: TEST Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with novel molding process
Description: TEST Lens
Study: NCT04634292

Intervention type: BEHAVIORAL
Intervention: EEG
Description: EEG + walking task + auditory task

Intervention type: BEHAVIORAL
Intervention: EEG
Description: EEG + walking task + auditory task

Intervention type: BEHAVIORAL
Intervention: EEG
Description: EEG + walking task + auditory task

Intervention type: BEHAVIORAL
Intervention: EEG
Description: EEG + walking task + auditory task
Study: NCT02627859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Durolane SJ
Description: 1ml single intra-articular injection in ankle
Study: NCT03701516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with current molding process
Description: CONTROL Lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A with current molding process
Description: CONTROL Lens
Study: NCT02245997

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: proton beam RT
Study: NCT04486573

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Magnetic Resonance Imaging
Description: A cardiac MRI is a painless imaging test that uses radiowaves, magnets, and a computer to create detailed pictures of the heart.
Study: NCT01539707

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin succinate suspension 5 mg
Description: Adolescents and children are given a single dose of solifenacin succinate liquid suspension orally via syringe in the morning of day 1 followed by a glass of water. Doses are calculated per weight of the participant, targeting to have equivalent dose of 5 mg dose of solifenacin once daily in adults (referred to as PED of 5 mg).
Study: NCT03461653

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine counselling
Description: women on web counselling
Study: NCT03950817

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg
Description: Nebulized Sub-dissociative Dose Ketamine at 0.75 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sub-dissociative Dose Ketamine at 1 mg/kg
Description: Nebulized Sub-dissociative Dose Ketamine at either 0.75 mg/kg, 1 mg/kg, and 1.5 mg/kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
Description: Nebulized Sub-dissociative Dose Ketamine at 1.5 mg/kg.
Study: NCT03564678

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Levocarnitine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B Complex
Description: Given PO
Study: NCT04070157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: Lofexidine 0.18 mg tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo tablets. Dosing will begin with 1 tablet administered every 5-6 hours, up to 4 times day. The dose may be titrated but not to exceed 4 tablets 4 times a day.
Study: NCT03900481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical gastric plication
Description: Vertical gastric plication ( without cutting gastric wall) is a novel surgical approach for reducing the stomach capacity. A transoral or endoluminal approach (i.e. a procedure that requires no incision, because access is granted through the mouth) offers some potential additional benefit to the patient, because the procedures continue to become more and more minimally invasive.
Study: NCT03931707

Intervention type: GENETIC
Intervention: Genomic sequencing
Description: Both sick and high-risk newborn un-randomized to receive genomic sequencing will receive a Genomic Newborn Sequencing Report which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
Study: NCT02531958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggs
Description: Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
Study: NCT03632057

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Tilt (65%)
Description: This is the standard group, so device programming for shock energy is the default setting

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed Pulse Width
Description: The device has to be programmed with fixed pulse width for each phase of the biphasic waveform
Study: NCT00142961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: atomoxetine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT06354127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP450
Description: The test drug or control drug is injected on the day of administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botox®
Description: The test drug or control drug is injected on the day of administration.
Study: NCT01018420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg capsule at the 6 hour point
Study: NCT00964808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
Study: NCT01564810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy of mFOLFOX6 or FOLFIRI
Description: FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy of mFOLFOX6 or FOLFIRI
Description: FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
Study: NCT01605539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 400
Description: Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
Study: NCT04549948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.017X0.025 Stainless steel
Description: Leveling curve of Sppe using 0.017X0.025 SS archwire

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 0.019X0.025 Stainless steel
Description: Leveling curve of Sppe using 0.019X0.025 Stainless steel archwire
Study: NCT01605539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 800
Description: Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
Study: NCT00539006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FPNS
Description: fluticasone propionate nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FPNS
Description: fluticasone propionate nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFNS
Description: fluticasone furoate nasal spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FFNS
Description: fluticasone furoate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FPNS
Description: placebo nasal spray matching fluticasone propionate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FPNS
Description: placebo nasal spray matching fluticasone propionate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FFNS
Description: placebo nasal spray matching fluticasone furoate nasal spray

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo FFNS
Description: placebo nasal spray matching fluticasone furoate nasal spray
Study: NCT03879759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NAC 2400mg/day
Description: 2400mg/day 2 x 600mg b.d

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 matched placebo tablets/day
Study: NCT00104962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally
Study: NCT00124709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimecrolimus
Description: Pimecrolimus cream 1 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: conventional corticosteroid-based treatment
Study: NCT06412380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant insertion
Description: All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant insertion
Description: All patients received a single Tapered Screw implant (Bioinnovation Dental®, Brazil). The implants were placed according to the manufacturer's instructions by using the appropriate burs with a final master drill of 3.5 or 4.5 mm in diameter by one senior oral surgeon. These implants were multi-threaded, and their surfaces were both sandblasted and acid etched. Of the 230 participants, 172 received a single 5 x 10-mm implant, and 58 received a 4 x 10-mm implant.
Study: NCT00989365

Intervention type: OTHER
Group type: OTHER
Intervention: Aerobic training
Description: Treadmill training
Study: NCT00595946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 24 mcg capsules twice daily (BID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mcg capsules twice daily (BID)
Study: NCT03062878

Intervention type: OTHER
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplesmography

Intervention type: OTHER
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplesmography

Intervention type: OTHER
Intervention: Arterial blood pressure
Description: Continuously monitored for 5-30 minutes via finger photoplesmography

Intervention type: OTHER
Intervention: Vascular Ultrasound
Description: Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter

Intervention type: OTHER
Intervention: Vascular Ultrasound
Description: Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter

Intervention type: OTHER
Intervention: Vascular Ultrasound
Description: Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter

Intervention type: OTHER
Intervention: Venous blood sample
Description: Evaluation of oxidative stress via serum lipid hydroperoxide

Intervention type: OTHER
Intervention: Venous blood sample
Description: Evaluation of oxidative stress via serum lipid hydroperoxide

Intervention type: OTHER
Intervention: Venous blood sample
Description: Evaluation of oxidative stress via serum lipid hydroperoxide

Intervention type: OTHER
Intervention: Skin microcirculatory blood flow
Description: Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.

Intervention type: OTHER
Intervention: Skin microcirculatory blood flow
Description: Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.

Intervention type: OTHER
Intervention: Skin microcirculatory blood flow
Description: Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
Study: NCT01199510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care
Description: Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
Study: NCT00964808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg \* 2 pr. day until time to discharge from the Hospital or latest at day 12.
Study: NCT01199510

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Post Cataract Surgery Standard of Care
Study: NCT00938392

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational FluNG vaccine GSK2186877A, aged lot
Description: Single dose, intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational FluNG vaccine GSK2186877A, fresh lot
Description: Single dose, intramuscular injection
Study: NCT00848666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical therapy
Description: One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
Study: NCT02487459

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501
Description: T cells transduced with CaspaCIDe suicide gene
Study: NCT01297673

Intervention type: PROCEDURE
Intervention: video-urodynamic examination
Description: Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
Study: NCT02487459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP1903
Description: dimerizer drug administered to treat GVHD
Study: NCT04391686

Intervention type: DIAGNOSTIC_TEST
Intervention: indirect calorimetry
Description: to determine and compare the resting energy expenditure of each group

Intervention type: DIAGNOSTIC_TEST
Intervention: indirect calorimetry
Description: to determine and compare the resting energy expenditure of each group

Intervention type: DIAGNOSTIC_TEST
Intervention: indirect calorimetry
Description: to determine and compare the resting energy expenditure of each group
Study: NCT00690846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg weekly adalimumab injection.
Study: NCT03105076

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aids
Description: Shared decision making with decision aids
Study: NCT02326337

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TWO2 Device
Description: Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Device
Description: Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
Study: NCT00265616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: liquid, mg/kg.h, titrated after EEG

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiopental/pentobarbital
Description: liquid, mg/kg.h, titrated after EEG
Study: NCT03684447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Series of 6 treatments with propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Series of 6 treatments with propofol. May be able to cross over and receive 6 additional treatments with the high dose of propofol.
Study: NCT05122949

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D Printed Ankle-Foot Orthosis
Description: 3D Printed (Fused Deposition Modelling) Ankle-Foot Orthosis with Polyamide Nylon-12 material

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermoformed Ankle-Foot Orthosis
Description: Thermoformed Ankle-Foot Orthosis with homopolymer polypropylene
Study: NCT02691767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Study: NCT01283048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BKM-120 Bevacizumab
Description: BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
Study: NCT02529410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac Resynchronisation Therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronisation Therapy
Study: NCT00774098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dextrose 10% (D10W ®) infusion
Description: Started at 8pm the day before surgery until the procedure begins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperinsulinemic normoglycemic clamp
Description: Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: high calorie diet 35 kcal/kg
Description: High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline (NS 0.9)
Description: Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
Study: NCT01177033

Intervention type: OTHER
Intervention: Best endovascular treatment or Best surgical treatment
Description: Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).

Intervention type: OTHER
Intervention: Best endovascular treatment or Best surgical treatment
Description: Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
Study: NCT00613600

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glucomannan
Description: Two 665 mg capsules of glucomannan three times a day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Inert microcrystalline cellulose
Description: Two capsules of inert microcrystalline cellulose three times a day for eight weeks
Study: NCT02175069

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene Nerve Block
Description: ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interscalene Nerve Block
Description: ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.75%, 20ml
Description: 20 ml of ropivacaine 0.75%
Study: NCT03209973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered as specified in the treatment arm